WORLD - A major study published in The Lancet has found that the human papillomavirus (HPV) vaccine has reduced cervical cancer deaths among women under 30 in the United Kingdom to effectively zero. Researchers describe it as one of the strongest real-world demonstrations of vaccine impact on cancer prevention.
The analysis was led by Queen Mary University of London and funded by Cancer Research UK, using national mortality data and long-term vaccination records since the UK introduced the HPV vaccine in 2008.
Zero Deaths Among Young Women
The study found that between 2020 and 2024, no women aged 20 to 24 died from cervical cancer in the UK. Researchers estimated that without vaccination, around 23 deaths would have been expected in this age group during the same period.
This marks a historic shift compared to earlier decades. Between 2000 and 2004, 25 women aged 20–24 died from cervical cancer, followed by 16 deaths in 2005–2009, 27 in 2010–2014, and five in 2015–2019 before falling to zero in the most recent five-year window.
What the Researchers Say
Experts say the results reflect both high vaccine effectiveness and strong public health uptake. Michelle Mitchell, chief executive of Cancer Research UK, called the findings “an incredible milestone,” noting that the HPV vaccine has now been shown to prevent deaths, not only infections or precancerous changes.
Researchers say the decline aligns closely with the generation first offered routine vaccination in schools after 2008.
How HPV Causes Cervical Cancer
Cervical cancer is primarily caused by persistent infection with high-risk strains of human papillomavirus (HPV), a very common virus transmitted through skin-to-skin sexual contact.
Most HPV infections clear naturally within about two years, but in some cases the virus persists and disrupts normal cell growth. Over time, this can lead to precancerous changes and eventually cervical cancer if untreated.
The disease often develops slowly and without symptoms in its early stages, making screening and vaccination critical tools for prevention.
According to the World Health Organization, cervical cancer causes about 660,000 new cases and 350,000 deaths globally each year, with more than 90 percent of deaths occurring in low- and middle-income countries.
Vaccination is considered the most effective prevention method, but global coverage remains uneven due to access issues and vaccine hesitancy. Several countries, including India, China, Pakistan, and Indonesia, have recently expanded national HPV vaccination programmes targeting adolescent girls.
Why the Findings Matter Globally
Public health experts say the UK results strengthen the case for global elimination efforts. The World Health Organization aims for 90 percent of girls worldwide to be fully vaccinated against HPV by age 15, alongside improved screening and treatment.
While researchers caution that continued monitoring is needed, the study provides strong evidence that widespread HPV vaccination can dramatically reduce, and potentially eliminate, cervical cancer deaths in future generations.
